Treatment Of Breast Cancer Research Articles

Do non-mammary conditions influence patients’ cosmetic perception after breast conserving surgery?

IntroductionCompared to mastectomy, breast-conserving surgery (BCS) guarantees equivalent local control and survival, with lower morbidity and better quality of life (QOL), even in the long term. However, some BCS patients consider the cosmetic result to be unsatisfactory, which may affect QOL.Material and methodsThis prospective, cross-sectional study included patients who underwent BCS. The patients answered the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ) - C30, EORTC QLQ-BR23 and Breast Cancer Treatment Outcome Scale (BCTOS) questionnaires, underwent cosmetic breast self-assessment and had their breasts photographed. The photographs were analyzed using Breast Cancer Conservative Treatment. Cosmetic results (BCCT.core). For the categorical variables, the frequencies were calculated; for the numerical variables, the mean and standard deviation. The BCCT.core results were compared with the cosmetic results of the patients, which yielded four possible results: concordant satisfaction, discordant satisfaction, concordant dissatisfaction and discordant dissatisfaction (satisfactory BCCT.core evaluation but patient dissatisfaction). The kappa test was used for agreement between categorical variables. Student’s t test and Mann-Whitney were used to assess the relationship between QOL and cosmetic results. The ANOVA were performed with the adjusted Bonferroni correction to compare the four groups.ResultsA total of 300 patients were evaluated, 298 underwent self-assessment of the breasts (76.8% satisfactory results and 23.2% unsatisfactory) and 297 underwent BCCT.core evaluation (29.9% satisfactory results and 79.1% unsatisfactory), which had a kappa of 0.095 (p = 0.01). In the self-assessment, patients with unsatisfactory cosmetic results had worse overall health, physical, functional, emotional, cognitive, and social capacity, fatigue, pain, dyspnea, financial difficulties, body image; future prospects, side effects, breast symptoms, functional aspects, cosmetics and edema. When we used software evaluation, these relationships did not have the same proportions. In patients with “discordant dissatisfaction”, higher pain scores and worse functionality on the treated side were found.ConclusionAn unsatisfactory cosmetic result was associated with worse QOL, which may be associated with other factors, such as breast pain and functionality.

18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Build machine learning (ML) models able to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on conventional and radiomic signatures extracted from baseline [18F]FDG PET/CT. Primary tumor and the most significant lymph node metastasis were manually segmented in baseline [18F]FDG PET/CT of 52 newly diagnosed BC patients. Clinical parameters, NAC and conventional semiquantitative PET parameters were collected. The standard of reference considered was surgical pCR after NAC (ypT0;ypN0). Eight-hundred-fifty-four radiomic features (RFts) were extracted from both PET and CT datasets, according to IBSI; robust RFTs were selected. The cohort was split in training (70%) and validation (30%) sets. Four ML Models (Clinical Model, CT Model, PET Model_T and PET Model_T + N) each one with 3 learners (Random Forest (RF), Neural Network and Stochastic Gradient Descendent) were trained and tested using RFts and clinical signatures. PET Models were built considering robust RFTs extracted from either primary tumor alone (PET Model_T) or also including the reference lymph node (PET Model_T + N). 72 pathological uptakes (52 primary BC and 20 lymph node metastasis) at [18F]FDG PET/CT were segmented. pCR occurred in 44.2% cases. Twelve, 46 and 141 robust RFts were selected from CT Model, PET Model_T and PET Model_T + N, respectively. PET Models showed better performance than CT and Clinical Models. The best performances were obtained by the RF algorithm of the PET Model_T + N (AUC = 0.83;CA = 0.74;TP = 78%;TN = 72%). ML models trained on PET/CT radiomic features extracted from primary BC and lymph node metastasis could concur in the prediction of pCR after NAC and improve BC management.

Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.

Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. CDCP1 expression was assessed immunohistochemically in tumors from 423 patients (119 triple-negative breast cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER2-targeting ADC T-DM1. Detection of CDCP1-expressing primary and metastatic xenografts in mice was examined by PET-CT imaging using 89zirconium-labelled ch10D7 (89Zr-ch10D7). The impact of ch10D7-MMAE on tumor burden and survival in vivo, including in combination with T-DM1, was quantified in cell line and patient-derived xenograft mouse models. CDCP1 is expressed predominantly on the surface of malignant cells of 70% of TNBCs, 80% of HER2+ tumors, and increases in ER+/HER2- tumors from 44.9% in primary tumors to 56.4% in lymph node metastases and 74.3% in distant metastases. PET-CT imaging with 89Zr-ch10D7 is effective for the detection of primary and metastatic CDCP1-expressing TNBCs in mice. ADC ch10D7-MMAE kills CDCP1-expressing cells in vitro and controls primary and metastatic TNBC xenografts in mice, conferring significant survival advantages over chemotherapy. It compares favorably to T-DM1 in vivo, and ch10D7-MMAE combined with T-DM1 showed the most potent efficacy, markedly reducing tumor burden of CDCP1+/HER2+ xenografts and prolonging mouse survival, compared with T-DM1 or ch10D7. CDCP1-directed molecular imaging has potential to identify aggressive breast cancers for CDCP1-targeted treatment.

Next generation antibody-drug conjugates in the treatment of her2-positive metastatic breast cancer: literature review and clinical case demonstration.

Breast cancer, along with its high incidence, is characterized by an extreme degree of tumor heterogeneity, which is reflected in the presence of molecular genetic classification and treatment algorithms based on immunohistochemical and mutational characteristics of the tumor. The revolution in the treatment of the HER2-positive subtype occurred about 25 years ago, when the first targeted drug trastuzumab came to clinical practice. Currently, there are a large number of treatment options for this subtype of breast cancer, including the most advanced drugs such as monoclonal antibody + cytotoxic agent conjugates. Trastuzumab deruxtecan is a new generation antibody–drug conjugate that has been registered in Russia and other countries as the therapy of choice in 2 and subsequent treatment lines for metastatic HER2-positive breast cancer. The article presents randomized clinical trials that formed the basis of these indications, and a phase IIIb/IV study DESTINY-Breast12 demonstrating high intracranial activity of this drug. The clinical case illustrates the effectiveness of trastuzumab deruxtecan in a late line in a pretreated patient with multiple metastasis including brain, as well as the possibility of diagnosing and correcting a specific adverse event such as interstitial lung disease.

Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes.

Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are the most common adverse effects experienced by breast cancer patients. This scoping review aimed to systematically synthesize the predictors/risk factors and outcomes of AIMSS in patients with early-stage breast cancer. A systematic search was conducted in PubMed, Web of Science, EMBASE, CINAHL, and the China National Knowledge Internet (CNKI) from inception to December 2024 following the scoping review framework proposed by Arksey and O'Malley (2005). A total of 5,008 studies were identified, and 98 were included in this review. The risk factors for AIMSS included psychosocial and demographic factors (e.g., age, BMI, menstrual status, and anxiety), clinical factors (e.g., history of chemotherapy, preexisting pain, and musculoskeletal diseases) and gene polymorphisms (e.g., ESR1, OPG, RANKL, TCL1A, and CYP19A1). The outcomes of AIMSS encompassed physical, psychological, behavioral, and survival-related impacts. This scoping review synthesized the available evidence on predictors, risk factors, and outcomes of AIMSS, providing a foundation for developing risk prediction models and enhancing symptom management strategies.

An Investigation of Travel Distance and Timeliness of Breast Cancer Treatment Among a Diverse Cohort in the United States

Travel to and from distant cancer treatment facilities can place a significant burden on cancer patients, particularly rural and minority survivors. Thus, the purpose of our investigation was to examine the association between patient travel distance and delays in types of treatment for breast cancer (surgery, radiation, chemotherapy, and hormonal therapy) and treatment delays. Using a novel linkage between the state cancer registry and administrative data from Medicaid and a private insurance plan, 2155 BC patients were successfully linked to create the cohort. ArcGIS was used to geocode all case residences and treatment facility addresses and calculate network distance between the residence and each facility. Logistic regression models were used to calculate the adjusted odds of being delayed versus timely by street distance. Odds of late surgery were increased by 1% (95% CI: 1.00, 1.01) for each one-mile increase from the patient’s residence to the treatment facility. In race-stratified models, the odds of late treatment for Black patients increased by 3% per mile (95% CI 1.01, 1.06) for radiation. Increased travel distance appears to significantly increase treatment delays for surgical, radiation, and chemotherapeutic treatments for women with BC, especially among Black women.

Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer.

This study presents T-1-NBAB, a new compound derived from the natural xanthine alkaloid theobromine, aimed at inhibiting VEGFR-2, a crucial protein in angiogenesis. T-1-NBAB's potential to interacts with and inhibit the VEGFR-2 was indicated using in silico techniques like molecular docking, MD simulations, MM-GBSA, PLIP, essential dynamics, and bi-dimensional projection experiments. DFT experiments was utilized also to study the structural and electrostatic properties of T-1-NBAB. Computational analysis was performed to predict the ADME-Tox profiles of T-1-NBAB. After semisynthesis, the in vitro results showed that T-1-NBAB effectively inhibits VEGFR-2, with an IC50 of 0.115 μM, compared to sorafenib's 0.0591 μM. In vitro tests also demonstrated significant activity of T-1-NBAB against breast cancer cell lines MCF7 and T47D, with IC50 values of 16.88 μM and 61.17 μM, respectively, and high selectivity. Importantly, T-1-NBAB induced early and late apoptosis in MCF7 cells, indicating its potential as a strong anticancer agent. Additionally, T-1-NBAB reduced the migration and healing abilities of MCF7 cells, suggesting it could be a promising anti-angiogenic agent. Overall, these findings suggest that T-1-NBAB is a promising lead compound for further research as a potential treatment for breast cancer.

Non-hormonal management of vasomotor symptoms during and after primary breast cancer treatment

Non-hormonal management of vasomotor symptoms during and after primary breast cancer treatment

Potential of Bioactive Compounds In Coleus amboinicus, Lour., Leaves Against Breast Cancer By Assessment Using A Network Pharmacology Approach and Cytotoxic Test

Breast cancer is a disease that significantly contributes to global women death. The study aims to conduct in vitro activity testing and assessment with a bioinformatics approach using a pharmacological network of bioactive compounds from bangun-bangun (Coleus amboinicus) leaves extract as a breast cancer drug. The methods used are extraction of bioactive compounds by maceration and partition, identification and analysis of bioactive compounds using the Liquid Chromatography High-Resolution Mass Spectrometry (LC-HRMS) instrument, cytotoxic testing of breast cancer cells (MCF-7) and normal cells (CV-1) with the MTT method, and assessment with a bioinformatics approach through a network pharmacology. The results of the cytotoxic test of ethyl acetate extract provided better activity with IC50 value of 102.30 and 457.09 µg/mL against MCF-7 cancer cells and CV-1 normal cells. The selectivity index value of 4.23 indicates the potential for further development in the treatment of breast cancer. The results of the analysis of chemical compound content show various types of potential bioactive compounds as breast cancer anticancer; assessment of the bioinformatics approach through networks pharmacology with pathways in cancer provides predictions of signal transducer and activator of transcription 3 (STAT3) protein as the main therapeutic mechanism target in breast cancer treatment. This study provides initial information for further research on testing and utilizing bioactive compounds from C. amboinicus leaves as an alternative treatment for breast cancer.

In situ generation of Copper sulfide within Poly(lactic-co-glycolic acid): A strategy for Safer photothermal therapy in Triple-Negative breast cancer.

Copper sulfide nanoparticles (CuS NPs) have garnered significant attention in photothermal therapy (PTT) owing to their facile synthesis, biodegradability, stability, and excellent photothermal conversion efficiency. Nonetheless, their potential toxic effects have restricted their application. This research focuses on the encapsulation of CuS NPs with the biocompatible polymer poly(lactic-co-glycolic acid) (PLGA) to enhance their biocompatibility, thereby improving the efficacy and safety of PTT in the treatment of triple-negative breast cancer (TNBC). Three distinct methods, namely aqueous phase loading method, oil phase loading method, and "in situ reduction" method were employed to synthesize PLGA-coated CuS (CuS@PLGA) NPs to optimize the encapsulation rate of CuS. Among these, the CuS@PLGA NPs fabricated via the "in situ reduction" method demonstrated the highest encapsulation efficiency for CuS, achieving a rate of (90.4 ± 3.3)%. The resulting CuS@PLGA NPs exhibited high stability, excellent photothermal effect, and good tumor-targeting ability. Moreover, CuS@PLGA NPs demonstrated enhanced anti-tumor efficacy and biocompatibility compared to CuS NPs in both in vitro and in vivo experiments. Consequently, this study offers an effective and safety strategy for PTT treatment of TNBC.

Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic?

We examined the impact of the COVID-19 consortium recommendations on the surgical management of breast cancer during the first year of the pandemic. Patients with newly diagnosed ER + DCIS, ER- DCIS, AJCC Stage cT1-2N0-1 ER + , HER2-, HER2 + , and triple negative breast cancer were identified from the National Cancer Database from 2018 to 2021. An interrupted time series design evaluated differences in surgical delay and use of neoadjuvant chemotherapy/immunotherapy (NAC) and endocrine therapy (NET) before and after the pandemic. A total of 895116 female patients were included in the study with a mean age of 61.7years. Time to surgery decreased by an average 5.5days from January 2020 to May 2020 for all breast cancer types, corresponding with a 62.2% decrease in breast cancer diagnoses per month from January 2020 to April 2020. The use of NET increased from 5.6 to 23.6% from January to March 2020 for patients with ER + DCIS and 8.0 to 31.1% for ER + cT1-2N0 cancer (both p < 0.01). The use of NAC for HER2 + tumors and triple negative breast cancers has been increasing since 2018 and a larger than expected increase was seen from 57.2 to 63.6% for HER2 + tumors and 55.6 to 68.7% for triple negative breast cancers (both p < 0.01). Treatment practices returned to pre-pandemic levels in June 2020. Prior to the publication of the Consortium recommendations, time to surgery decreased while the use of NET and NAC increased, with the resumption of pre-pandemic practices by June 2020.

Global transcriptome profiling of ST09 treated breast cancer cells identifies miR-197-5p/GPX3 antioxidant axis as a regulator of tumorigenesis.

ROS (Reactive Oxygen Species) has a dual role in tumorigenesis. Some cancers have high ROS conditions, and others have low ROS. TNBC thrives on high ROS compared to other Breast Cancer subtypes. Several antioxidant enzymes catalyze the detoxification of reactive oxygen species and prevent free radicals from damaging DNA and accumulation of mutation. Curcumin, a polyphenol dietary supplement, acts as a potent antioxidant, is known to reduce inflammation, and has anticancer properties. Here, we aim to understand alterations in the transcriptome (miRNA and mRNA expression) induced by ST09 in breast cancer cell lines. We identified an antioxidant system that is upregulated in breast cancer cell lines. Among the antioxidant enzymes regulated by miRNA was GPX3. A novel miRNA-mRNA antioxidant axis, miR-197-5p/GPX3, was observed in the TNBC cell line. We further validated the regulation of GPX3 by miRNA using luciferase assay. GPX3 overexpression, knockdown, and activity assay indicated the anti-tumorigenic role of GPX3 in the TNBC cell line. Further, treatment of TNBC xenograft with ST09 showed tumor reduction in vivo. ST09 potentiates the effect of standard-of-care (SOC) drug Cisplatin in vivo. ST09 can be exploited as a single chemotherapeutic agent or in combination treatment modalities, reducing the dosage of potent drugs.

Investigation of Aframomum melegueta compounds as ERK5 inhibitor related to breast cancer via molecular docking and dynamic simulation.

The molecular docking study of Dihydrogingerenone A, 1-(3, 4-dihydroxy-5-methoxyphenyl)-7-(3, 4-dihydroxyphenyl) heptane-3, 5-diyldiacetate, and Dihydrogingerenone C from Aframomum melegueta as effective breast cancer treatment.

Liquid biopsy technologies: innovations and future directions in breast cancer biomarker detection.

Globally, breast cancer is the most frequent type of cancer, and its early diagnosis and screening can significantly improve the probability of survival and quality of life of those affected. Liquid biopsy-based targets such as circulating tumor cells, circulating tumor DNA, and exosomes have been instrumental in the early discovery of cancer, and have been found to be effective in stage therapy, recurrence monitoring, and drug selection. Biosensors based on these target related biomarkers convert the tested substances into quantifiable signals such as electrical and optical signals through signal transduction, which has the advantages of high sensitivity, simple operation, and low invasiveness. This review provides an overview of the latest progress of liquid biopsy biomarkers in the diagnosis, prognosis and treatment of breast cancer, compares the application and advantages of different biosensors based on these biomarkers in the diagnosis of breast cancer, and analyzes the limitations and solutions of biosensor based methods.

Predicting Optimal Chemotherapy Regimens in Breast Cancer Treatment using Machine Learning

Breast cancer treatment involves personalized chemotherapy regimens to improve patient outcomes, and selecting the optimal regimen is a crucial challenge. Machine learning (ML) algorithms offer potential solutions by analyzing complex clinical data and predicting effective treatment strategies. This study conducts a comparative analysis of multiple ML algorithms, including decision trees, support vector machines, neural networks, and ensemble methods, to predict the optimal chemotherapy regimens for breast cancer patients. Using a dataset comprising clinical, pathological, and molecular features, the models are trained and evaluated based on accuracy, sensitivity, specificity, and predictive power. The results demonstrate that ensemble methods outperform other approaches, offering higher prediction accuracy and robustness. Feature importance analysis further highlights significant predictive factors for chemotherapy response. This comparative study provides valuable insights into the strengths and limitations of various ML algorithms in the context of personalized chemotherapy for breast cancer, contributing to more informed decision-making and potentially enhancing treatment efficacy.

Harnessing Polyphenols and Novel Delivery Strategies for Effective Treatment of Breast Cancer.

Breast cancer continues to pose a significant global health challenge, with conventional therapies frequently hindered by resistance mechanisms and undesirable side effects. This review investigates the therapeutic potential of polyphenols-naturally occurring compounds recognized for their antioxidant, anti-inflammatory, and anti-cancer properties-as alternative or complementary treatments for breast cancer. We examine the molecular pathways through which polyphenols exert their effects, including their influence on oxidative stress modulation, inflammatory responses, cellular proliferation, apoptosis, and estrogen receptor signalling. Additionally, this review addresses innovative nano-based drug delivery systems such as nanoparticles, liposomes, niosomes, and phytosomes that enhance the stability, bioavailability, and targeted delivery of polyphenols. These advanced formulations aim to overcome challenges related to polyphenol degradation, low solubility, and rapid systemic clearance, thereby enhancing their therapeutic efficacy. Through a detailed analysis, we assess the contributions of various nanocarriers in optimizing the delivery of polyphenols specifically to breast cancer cells while minimizing systemic toxicity. The evidence presented highlights the potential of polyphenols in breast cancer management, further supported by nanoformulations that improve both stability and delivery efficiency.

Interactions between the tumor microbiota and breast cancer

Breast cancer is the most common malignancy in women worldwide. Changes in the microbiota and their metabolites affect the occurrence and development of breast cancer; however, the specific mechanisms are not clear. Gut microbes and their metabolites influence the development of breast cancer by regulating the tumor immune response, estrogen metabolism, chemotherapy, and immunotherapy effects. It was previously thought that there were no microorganisms in breast tissue, but it is now thought that there are microorganisms in breast cancer that can affect the outcome of the disease. This review builds on existing research to comprehensively analyze the role of gut and intratumoral microbiota and their metabolites in the development and metastasis of breast cancer. We also explore the potential function of the microbiota as biomarkers for prognosis and therapeutic response, highlighting the need for further research to clarify the causal relationship between the microbiota and breast cancer. We hope to provide new ideas and directions for the development of new methods for breast cancer treatment.

Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Triple-negative breast cancer (TNBC) is a highly metastatic subtype of breast cancer. The epithelial-to-mesenchymal transition is a nonbinary process in the metastatic cascade that generates tumor cells with both epithelial and mesenchymal traits known as hybrid EM cells. Recent studies have elucidated the enhanced metastatic potential of cancers featuring the hybrid EM phenotype, highlighting the need to uncover molecular drivers and targetable vulnerabilities of the hybrid EM state. Here, we discovered that hybrid EM breast tumors are enriched in CD38, an immunosuppressive molecule associated with worse clinical outcomes in liquid malignancies. Altering CD38 expression in tumor cell impacted migratory, invasive, and metastatic capabilities of hybrid EM cells. Abrogation of CD38 expression stimulated an antitumor immune response, thereby preventing the generation of an immunosuppressive microenvironment in hybrid EM tumors. CD38 levels positively correlated with PD-L1 expression in samples from patients with TNBC. Moreover, targeting CD38 potentiated the activity of anti-PD-L1, eliciting strong antitumor immunity, with reduced tumor growth in hybrid EM models. Overall, this research exposes upregulation of CD38 as a specific survival strategy utilized by hybrid EM breast tumors to suppress immune cell activity and sustain metastasis, with strong implications in other carcinomas that have hybrid EM properties. Significance: Hybrid cells co-featuring epithelial and mesenchymal traits in triple-negative breast cancer express elevated levels of CD38 to induce immunosuppression and metastasis, indicating CD38 inhibition as potential strategy for treating breast cancer.

Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real-World Data.

The liver is crucial for metabolizing the anticancer drug palbociclib, but limited information is available on the impact of hepatic impairment on its toxicity and efficacy, with no real-world data available. This study aims to evaluate how hepatic impairment affects hematological toxicity and progression-free survival (PFS) of palbociclib in advanced hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, using the National Cancer Institute scoring system, in a large real-world dataset. This multicenter retrospective observational study included female patients treated with palbociclib between August 2017 and February 2024. Regression analysis was used to compare the risk of developing grade 3/4 hematological toxicity and PFS between patients with normal and mild impaired liver function. In total, 478 female patients were included. Patients with mild hepatic impairment (n = 205) did not have an increased risk of developing grade 3/4 neutropenia compared with patients with normal hepatic function (n = 273) (hazard ratio (HR) = 1.11; 95% CI 0.83-1.47). In addition, the PFS was not significantly different between both groups (HR = 1.15; 95% CI 0.93-1.42). In real-world settings, patients with mild hepatic impairment do not have a higher risk of developing palbociclib-induced neutropenia or disease progression than patients with normal hepatic function. These findings can guide clinicians when treating breast cancer patients with mild hepatic impairment.

Anti-proliferative and Pro-apoptotic Activity of a Novel Oil-in-Water Nanoemulsion Containing Tea Tree Oil, Quercetin, and Rosmarinic Acid in Breast Cancer Cells

Cancer is one of the main causes of death across major mammalian orders, being the mammary gland tumor the most frequent in females. Surgery is the most widely used prescription for this condition; however, due to its side effects, new and less invasive treatments using bioactive compounds are being sought. Nanostructured systems, such as nanoemulsions (NEs), enable more efficient delivery and protection of these compounds, allowing it to reach its site of action more effectively. The present study aimed to develop oil-in-water (O/W) NEs with tea tree essential oil integrating quercetin, rosmarinic acid, or both and evaluate them as potential therapeutic agents in breast cancer cells. The NEs were characterized by particle size distribution and Z-potential for 4 weeks. Subsequently, their impact on cell viability was assessed in MDA-MB-231 cells, a triple-negative breast cancer cell line. The four NEs had an average size within the nanometer scale (10–9 m), ideal to passive target the anticancer effect (< 200 nm) due to the retention effect and facilitate its permeability. These vehicles were kept stable at 4 °C for 4 weeks. Our findings demonstrate that with initial doses of 3.9 μg/mL of these NEs, significant antiproliferative activity is achieved in cancer cells (~ 80%, p < 0.001); furthermore, the induction of apoptosis through caspase activation was demonstrated in MDA-MB-231 cells. In summary, our preliminary results suggest that nanoemulsions (NEs) of tea tree oil incorporating the bioactive compounds uercetin and rosmarinic acid may have potential therapeutic applications as co-adjuvant treatment of human breast cancer.